Ruben A Mesa

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint New drugs for the treatment of myelofibrosis
    Ruben A Mesa
    Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Curr Hematol Malig Rep 5:15-21. 2010
  2. doi request reprint Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis
    Krisstina Gowin
    Mayo Clinic, 13499E Shea Blvd, Scottsdale, AZ 85259, USA 480 301 8335 480 301 4675
    Expert Opin Investig Drugs 22:1603-11. 2013
  3. pmc Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial
    Ruben A Mesa
    Mayo Clinic, Scottsdale, AZ, USA
    Haematologica 98:1421-3. 2013
  4. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
  5. doi request reprint Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
    Ruben A Mesa
    Mayo Clinic, Scottsdale, AZ 85259, USA
    Leuk Res 37:911-6. 2013
  6. doi request reprint Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
    Ruben A Mesa
    Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    J Clin Oncol 31:1285-92. 2013
  7. pmc The evolving treatment paradigm in myelofibrosis
    Ruben A Mesa
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leuk Lymphoma 54:242-51. 2013
  8. doi request reprint Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
    Robyn M Emanuel
    Division of Hematology and Oncology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    J Clin Oncol 30:4098-103. 2012
  9. pmc Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
    Krisstina Gowin
    University of Southern California, USA
    Haematologica 97:1570-3. 2012
  10. ncbi request reprint Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 32:403-13. 2005

Research Grants

Detail Information

Publications91

  1. doi request reprint New drugs for the treatment of myelofibrosis
    Ruben A Mesa
    Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Curr Hematol Malig Rep 5:15-21. 2010
    ..Future targeted agents, and perhaps combinations of agents that currently show complementary benefits, are anticipated to further enhance the efficacy of medical therapy for MF...
  2. doi request reprint Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis
    Krisstina Gowin
    Mayo Clinic, 13499E Shea Blvd, Scottsdale, AZ 85259, USA 480 301 8335 480 301 4675
    Expert Opin Investig Drugs 22:1603-11. 2013
    ....
  3. pmc Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial
    Ruben A Mesa
    Mayo Clinic, Scottsdale, AZ, USA
    Haematologica 98:1421-3. 2013
    ..If future studies incorporate bevacizumab in combination therapy for myelofibrosis, more modest doses should be considered. (clinicaltrials.gov Identifier 00667277). ..
  4. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
    ..Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells...
  5. doi request reprint Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
    Ruben A Mesa
    Mayo Clinic, Scottsdale, AZ 85259, USA
    Leuk Res 37:911-6. 2013
    ..The consequences of delayed intervention should be assessed in the management of patients with myelofibrosis and treatment should be considered as clinically indicated for symptomatic relief or splenomegaly control. ..
  6. doi request reprint Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
    Ruben A Mesa
    Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    J Clin Oncol 31:1285-92. 2013
    ..0 to measure meaningful changes in myelofibrosis-related symptoms in patients with myelofibrosis...
  7. pmc The evolving treatment paradigm in myelofibrosis
    Ruben A Mesa
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leuk Lymphoma 54:242-51. 2013
    ..Data on JAK2 inhibitors, their role in an evolving treatment paradigm, and future directions for treatment of MF are discussed...
  8. doi request reprint Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
    Robyn M Emanuel
    Division of Hematology and Oncology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    J Clin Oncol 30:4098-103. 2012
    ..We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy...
  9. pmc Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
    Krisstina Gowin
    University of Southern California, USA
    Haematologica 97:1570-3. 2012
    ..We retrospectively analyzed 118 myeloproliferative patients who underwent pegylated interferon alpha-2a treatment. Responses were evaluated by ELN, IWG-MET and EUMNET standardized criteria sets and adverse effects were analyzed...
  10. ncbi request reprint Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 32:403-13. 2005
    ..Novel therapies aimed at the pathogenesis of the disorder are needed for more efficacious and targeted therapy of MMM...
  11. ncbi request reprint A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    R A Mesa
    Division of Hematology, Rochester, MN, USA
    Leukemia 21:1964-70. 2007
    ..8 nM) seen in pretreatment samples. The current study indicates both in vitro and in vivo tipifarnib activity in PMF and post-PV/ET MF...
  12. doi request reprint New insights into the pathogenesis and treatment of chronic myeloproliferative disorders
    Ruben A Mesa
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St S W, Rochester, Minnesota 55905, USA
    Curr Opin Hematol 15:121-6. 2008
    ..This review focuses on the implications of these changes relative to current standards...
  13. ncbi request reprint Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Blood 105:973-7. 2005
    ..Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered...
  14. doi request reprint The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
    Ruben A Mesa
    Mayo Clinic, Rochester, MN, USA
    Leuk Res 33:1199-203. 2009
    ..The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials...
  15. ncbi request reprint Pegylated interferon for the treatment of high-risk essential thrombocythemia
    Ruben Mesa
    Division of Hematology and Internal Medicine, Division of Hematopathology, Cancer Center Statistics Unit, Mayo Clinic, Rochester, USA
    Haematologica 90:1298B. 2005
  16. ncbi request reprint Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options
    Ruben A Mesa
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Best Pract Res Clin Haematol 19:495-517. 2006
    ..Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM...
  17. ncbi request reprint The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients
    Ruben A Mesa
    Department of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:68-76. 2007
    ..Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD)...
  18. ncbi request reprint Tipifarnib: farnesyl transferase inhibition at a crossroads
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 6:313-9. 2006
    ..US FDA approval for tipifarnib awaits results of subsequent Phase III trials of the agent in elderly acute leukemia...
  19. ncbi request reprint Practical management of classical myeloproliferative disorder patients: a clinician's guide
    Ruben A Mesa
    Mayo Clinic, Division of Hematology and Internal Medicine, 200 First Street, SW Rochester, MN 55905, USA
    Future Oncol 2:515-24. 2006
    ..Recent elucidation of the role of the activating tyrosine kinase mutation JAK2 (V617F) is anticipated to usher in an era of greater understanding and targeted therapy for the MPDs...
  20. ncbi request reprint Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia
    R A Mesa
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 20:1800-8. 2006
    ..008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis...
  21. ncbi request reprint Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 107:361-70. 2006
    ..The authors retrospectively analyzed their experience with splenectomy over the course of 30 years to analyze the impact of improved techniques, antimicrobials, and aggressive postoperative control of platelet counts on outcome...
  22. ncbi request reprint JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States
    Leuk Res 30:1457-60. 2006
    ....
  23. doi request reprint How I treat symptomatic splenomegaly in patients with myelofibrosis
    Ruben A Mesa
    Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 113:5394-400. 2009
    ..Future care of MF patients, including splenomegaly management, will continue to require the hematologist to select therapeutic options carefully in the context of realistic, achievable goals...
  24. doi request reprint Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis
    Ruben A Mesa
    Mayo Clinic, Division of Hematology Oncology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Expert Opin Emerg Drugs 14:471-9. 2009
    ..The future may well see the approval of a range of agents for MF patients, with differing mechanisms of action, efficacy and toxicity profiles...
  25. ncbi request reprint Myelofibrosis with myeloid metaplasia: therapeutic options in 2003
    Ruben A Mesa
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Rep 2:264-70. 2003
    ..Debilitating constitutional symptoms improve with the pharmacologic blockage of tumor necrosis factor-alpha. Further molecular understanding of MMM is necessary for more effective targeted therapies...
  26. doi request reprint Assessing new therapies and their overall impact in myelofibrosis
    Ruben A Mesa
    Mayo Clinic, Scottsdale, AZ 85259, USA
    Hematology Am Soc Hematol Educ Program 2010:115-21. 2010
    ..Future advancements in the efficacy of MF-targeted therapy will likely arise from new pathogenetic insights and from combining JAK2 inhibitors with other agents...
  27. ncbi request reprint Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
    Ruben A Mesa
    Mayo Clinic, Division of Hematology and Oncology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    IDrugs 13:394-403. 2010
    ..Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clinical indications...
  28. doi request reprint Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
    Ruben A Mesa
    Department of Hematology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Cancer 117:4869-77. 2011
    ..The authors previously developed a MF-specific instrument for capturing the burden of MF-associated disease-related symptoms, the Myelofibrosis Symptom Assessment Form...
  29. ncbi request reprint Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, the Division of Hematopathology, and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4131-7. 2002
    ..0001). However, with the current duration of follow-up available on the patients, none of the histologic features evaluated have yet demonstrated prognostic value for subsequent clinical course, vascular events, or survival...
  30. doi request reprint Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 2:25-33. 2007
    ..In this article, we review both the old and new pharmacologic options for MMM...
  31. pmc Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
    Ruben A Mesa
    Mayo Clinic, Scottsdale, AZ, USA
    Blood 116:4436-8. 2010
    ..Lenali-domide and prednisone for myelofibro-sis evaluated through a multicentered-cooperative group mechanism is only modestly active and myelosuppre-sive. This study was registered at http://clinicaltrials.gov as NCT00227591...
  32. ncbi request reprint Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 108:1158-64. 2006
    ..We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities...
  33. ncbi request reprint MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
    Animesh D Pardanani
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 108:3472-6. 2006
    ..Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease...
  34. ncbi request reprint A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2534-41. 2003
    ..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
  35. ncbi request reprint Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Stem Cells 25:2358-62. 2007
    ..These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell...
  36. doi request reprint The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea
    Shireen Sirhan
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:363-5. 2008
    ..02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV...
  37. ncbi request reprint Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time
    Terra L Lasho
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 135:683-7. 2006
    ..We conclude that MPLW515L/K and JAK2V617F are both early events in MMM and allele burden, rather than the mere presence of these mutations, might be relevant to phenotypic variation in myeloproliferative disorders...
  38. ncbi request reprint The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:320-8. 2005
    ....
  39. doi request reprint Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms
    Raoul Tibes
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mol Diagn Ther 16:269-83. 2012
    ..Future clinical development will focus on optimal combination partners and agents that target alternative mechanisms, deepen the response, and achieve molecular remissions...
  40. doi request reprint Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
    Kebede Hussein
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 82:255-9. 2009
    ..The presence of 0, 1, 2, and > or =3 adverse factors defines low, intermediate-1, intermediate-2, and high risk disease, respectively. We examined the additional prognostic relevance of karyotype...
  41. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  42. ncbi request reprint Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 106:623-30. 2006
    ..The current study describes the natural history of AMM in transplant-eligible patients and proposes a new prognostic scoring system that favorably compares with other established models...
  43. ncbi request reprint Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1739-43. 2006
    ..For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo)...
  44. ncbi request reprint Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2083-8. 2007
    ..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
  45. ncbi request reprint Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 32:691-8. 2008
    ..Within the limitations of self-reported data, these results provide a benchmark for future interventions to improve QOL in patients with MDS...
  46. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
    ..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
  47. doi request reprint Risk factors for leukemic transformation in patients with primary myelofibrosis
    Jocelin Huang
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 112:2726-32. 2008
    ..However, to the authors' knowledge, information regarding risk factors for leukemic transformation in primary myelofibrosis is limited...
  48. doi request reprint Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
    Madappa N Kundranda
    Division of Hematology Oncology, Department of Internal Medicine, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Hematol Malig Rep 7:78-86. 2012
    ..This review focuses on the latest advances in our understanding of the biology of leukemic transformation and current clinical therapies that are available for this patient population...
  49. pmc Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia
    Scott H Kaufmann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Haematologica 96:1619-26. 2011
    ..We report here the results of a phase I and pharmacological study of the cytarabine + tanespimycin combination in adults with recurrent or refractory acute leukemia...
  50. doi request reprint Pomalidomide is active in the treatment of anemia associated with myelofibrosis
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester MN 55905, USA
    J Clin Oncol 27:4563-9. 2009
    ..However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...
  51. ncbi request reprint Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 103:3547-8. 2004
    ..However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not in itself sufficient for the diagnosis of PV...
  52. ncbi request reprint Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia
    Brijesh Arora
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Haematologica 89:1454-8. 2004
    ..This issue is further examined in the current prospective study and clinico-pathological correlates sought...
  53. ncbi request reprint Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study
    David P Steensma
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 99:2252-4. 2002
    ..Toxicity was mild, with injection site reactions (20%) and minor infections (10%) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM...
  54. ncbi request reprint Thalidomide treatment in myelofibrosis with myeloid metaplasia
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 117:288-96. 2002
    ..A lower dose of the drug might be more tolerable without compromising therapeutic value. Patients with PTMM and/or markedly increased circulating CD34+ cell counts might be susceptible to thalidomide-induced thrombocytosis...
  55. doi request reprint International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens
    Prakash Thapaliya
    Division of Hematology Oncology, Mayo Clinic Scottsdale, Arizona, USA
    Am J Hematol 86:96-8. 2011
    ..After a median follow-up of three years, fourteen patients (28%) had expired from MF at the time of this analysis with median survival of 36 months...
  56. ncbi request reprint Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients
    Brijesh Arora
    Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 128:42-8. 2005
    ..The current prospective study does not support an independent prognostic value for PB CD34 count in MMM...
  57. ncbi request reprint Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 106:1985-9. 2006
    ..Such information is particularly crucial for management decisions in transplant-eligible patients...
  58. doi request reprint Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not
    Ayalew Tefferi
    Division of Hematology Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:265-7. 2009
    ..003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value...
  59. ncbi request reprint Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 74:47-53. 2005
    ..In addition, it is unclear whether patients with MDS-associated acquired alpha thalassaemia (ATMDS), a special subgroup with a very high incidence of point mutations in the ATRX gene, have an especially high incidence of RUNX1 mutations...
  60. ncbi request reprint Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Ross L Levine
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 7:387-97. 2005
    ..In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase...
  61. ncbi request reprint Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:2210-6. 2002
    ..To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma...
  62. ncbi request reprint Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  63. ncbi request reprint Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Intern Med 43:540-7. 2004
    ..Among the novel agents tested, thalidomide seems the most promising although newer agents are on the horizon...
  64. ncbi request reprint Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:883-9. 2004
    ..To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with myeloid metaplasia (MMM)...
  65. doi request reprint JAK2 inhibitors and their impact in myeloproliferative neoplasms
    Holly L Geyer
    Department of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA
    Hematology 17:S129-32. 2012
    ....
  66. ncbi request reprint Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia
    Leonardo N Faoro
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Eur J Haematol 74:117-20. 2005
    ..The purpose of this study is to provide long-term follow-up on the durability of response in the initial cohort and in additional subsequent cases...
  67. ncbi request reprint Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 45:1545-9. 2004
    ..021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions...
  68. ncbi request reprint Extramedullary hematopoiesis
    Bettina Knoll
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 83:171. 2008
  69. ncbi request reprint PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis
    Apollina Goel
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Exp Hematol 33:784-95. 2005
    ..We investigated the potential of enhancing the radiosensitivity of myeloma cells by combining with PS-341; the underlying mechanisms were delineated...
  70. ncbi request reprint Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia
    Naseema Gangat
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:2406-11. 2006
    ..There is currently insufficient evidence to either support or refute an association between estrogen-based hormone treatment (EBHT) and thrombosis risk in essential thrombocythemia (ET)...
  71. ncbi request reprint Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment
    Cody A Koch
    Mayo Medical School, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:1223-33. 2003
    ..To define associated clinical conditions, pathology, natural history, and treatment outcome of nonhepatosplenic extramedullary hematopoiesis (NHS-EMH)...
  72. ncbi request reprint Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates
    Ayalew Tefferi
    Division of Hematology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 30:677-80. 2006
    ..In the current study, we show that microcytosis is a frequent laboratory feature in agnogenic myeloid metaplasia and investigate its clinical relevance in the particular setting...
  73. ncbi request reprint In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia
    R A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 17:849-55. 2003
    ....
  74. doi request reprint Future therapies for the myeloproliferative neoplasms
    Robyn Scherber
    Division of Hematology and Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, USA
    Curr Hematol Malig Rep 6:22-7. 2011
    ..Many questions remain as to the optimal JAK2 inhibitory strategy and the full extent of the benefit of single-agent JAK2 inhibition...
  75. ncbi request reprint A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies
    S Vincent Rajkumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Hematother Stem Cell Res 11:33-47. 2002
    ..Background information on pathogenesis and laboratory methods of quantifying bone marrow angiogenesis is also discussed...
  76. doi request reprint Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 22:756-61. 2008
    ..We conclude that low V617F allele burden in PMF might indicate the presence of an overriding V617F-negative clone that confers a more aggressive disease phenotype...
  77. ncbi request reprint Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Br J Haematol 113:763-71. 2001
    ..Instead, +8, 12p-, advanced age and anaemia were independent prognostic determinants of inferior survival. In particular, survival was not adversely affected by the presence of either 20q- or 13q-...
  78. ncbi request reprint The therapy of myelofibrosis: targeting pathogenesis
    Ruben A Mesa
    Division of Hematology, Mayo Clinic Rochester, MN, USA
    Int J Hematol 76:296-304. 2002
    ....
  79. ncbi request reprint Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders
    Ruben A Mesa
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Int J Hematol 76:193-203. 2002
    ..Palliative strategies which currently focus on non-specific myelosuppresion, will hopefully be soon replaced by targeted therapies as insight into pathogenetic mechanisms of these diseases evolves...
  80. ncbi request reprint Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia
    D Behl
    Department of Medicine, Mayo College of Medicine, Rochester, MN 55905, USA
    Leukemia 20:29-34. 2006
    ..Multivariate analysis demonstrated ALC > or = 500 cells/microl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of lymphocyte (immune) recovery on survival after IC in AML...
  81. ncbi request reprint Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia
    R A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 97:3665-7. 2001
    ..These observations support the bone marrow origin of the myeloid progenitor pool in the spleen of patients with MMM and suggest a prognostic value for splenic histopathology and karyotype. (Blood. 2001;97:3665-3667)..
  82. ncbi request reprint A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia
    R A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 114:111-3. 2001
    ..The overall lack of clinical benefit correlated with no significant improvement in the bone marrow morphological features of the disease. We conclude that pirfenidone has no significant clinical or biological activity in MMM...
  83. ncbi request reprint Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis
    M A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Res 31:1503-9. 2007
    ..0001). The independent prognostic value of monocytosis was validated in a separate database of 97 patients with PMF from another institution...
  84. ncbi request reprint Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia
    A Tefferi
    Division of Hematology and Internal Medicine and Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Eur J Haematol 66:37-42. 2001
    ..CONCLUSIONS: Low-dose abdominal RT for symptomatic hepatomegaly or ascites associated with advanced-stage MMM is myelosuppressive and provides only temporary and mainly subjective and short-lived relief...
  85. ncbi request reprint Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia
    Ching Liang Ho
    Division of Hematology and Oncology, Department of Medicine, Tri Service General Hospital, National Defense Medical Center, Taipei, Taiwan
    Eur J Haematol 74:35-9. 2005
    ..However, VEGF might contribute to the process in the early stages of the disease...
  86. ncbi request reprint Adverse events after imatinib mesylate therapy
    Michelle A Elliott
    N Engl J Med 346:712-3. 2002
  87. ncbi request reprint A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points
    Ruben A Mesa
    Haematologica 91:415-6. 2006
    ..6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation...
  88. ncbi request reprint Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?"
    Richard T Maziarz
    Mayo Clin Proc 78:941-3. 2003
  89. ncbi request reprint Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate
    Ruben A Mesa
    Br J Haematol 123:366-7. 2003
  90. ncbi request reprint Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow
    David P Steensma
    Haematologica 88:1072-4. 2003
  91. ncbi request reprint The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges
    Ruben A Mesa
    Leuk Res 31:883-6. 2007

Research Grants1

  1. Apoptosis in myelofibrosis with myeloid metaplasia
    Ruben Mesa; Fiscal Year: 2006
    ..abstract_text> ..